Bristol-Myers Squibb & Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) & VE800 in Pa...

Bristol-Myers Squibb Company (NYSE:BMY) and Vedanta Biosciences today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's programmed death-1 (PD-1) immune checkpoint inhibitor ...

Bristol-Myers Squibb, Vedanta Biosciences enter clincal trail to evaluate Opdivo and VE800 in patients with advanced/metastatic cancers

Opdivo (nivolumab) as a single agent is indicated for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. Opdivo (nivolumab), in combination with Yervoy (ipilimumab ...